ArticleLife (Basel, Switzerland)2024
New-Onset Hidradenitis Suppurativa in Psoriasis Patients: A Multi-Center, Retrospective Cohort Study.
Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Association of human papillomavirus infection with increased new-onset periodontitis risk: A multi-center retrospective cohort study.Journal of periodontology · 2026Article
- Risk of irritable bowel syndrome in patients with hidradenitis suppurativa: a global-federated, multicenter cohort study.Scientific reports · 2026Observational
- Risk of new-onset glaucoma in people with carpal tunnel syndrome: a global-federated, multicenter retrospective cohort study.International journal of medical sciences · 2026Article
- New-onset Autoimmune Diseases in Patients with Prurigo Nodularis: A Global-federated Retrospective Cohort Study.Acta dermato-venereologica · 2025Article
- Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders.International journal of molecular sciences · 2025Review
- Letter to the editor on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".Clinical and molecular hepatology · 2025Article
- Renal dysfunction in people with hidradenitis suppurativa: a multi-center, propensity-score-matched cohort study.International journal of medical sciences · 2025Article
- New-onset obstructive sleep apnea and insomnia after total knee replacement in patients with osteoarthritis: real-world evidences.Therapeutic advances in musculoskeletal disease · 2025Article
- Psoriasis Patients are Associated with Increased Risk of New-Onset Irritable Bowel Syndrome: A Multicenter, Retrospective Cohort Study.International journal of medical sciences · 2025Article
- Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on "Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study".Clinical and molecular hepatology · 2024Article
- Patients with hidradenitis suppurativa are associated with risk of new-onset glaucoma: a propensity-score-matched cohort study.International journal of medical sciences · 2024Article
- Risk of Hidradenitis Suppurativa in Patients With Carpal Tunnel Syndrome: A Population-based Cohort Study.In vivo (Athens, Greece)Article
- New-onset Bipolar Disorder in Hidradenitis Suppurativa Patients: A Multi-center, Propensity-score-matched Cohort Study.In vivo (Athens, Greece)Article
- Gout Risk After Total Knee Arthroplasty: A Propensity-score-matched Cohort Study.In vivo (Athens, Greece)Article
- Thyroid Diseases After Total Knee Replacement: A Multi-center, Propensity-score-matched Cohort Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPrevious research has indicated a potential correlation between hidradenitis suppurativa (HS) and psoriasis (PSO), two chronic inflammatory dermatological diseases. However, there is a lack of comprehensive evaluations that consider a variety of clinical and demographic factors, and the risk of developing HS in PSO patients remains unclear. Our study aims to examine HS risk over time among PSO patients versus matched controls while considering the influence of confounders to provide insights into the potential link between these two diseases.
methodIn this multi-institutional cohort study using the TriNetX database, we matched 202,318 patients with PSO with an equivalent number of individuals without PSO, using propensity score matching. The study period extended from 1 January 2005 to 31 December 2018. We computed hazard ratios and their respective 95% confidence intervals (CIs) to evaluate the probability of HS manifestation over a period of 5 years in patients with PSO in comparison to those without PSO.
resultsPSO patients demonstrated a consistently higher risk of developing HS than matched controls across all analytic models with the hazard ratios (HR) ranging from 1.43 (95% CI 1.30-1.56) to 5.91 (95% CI 2.49-14.04). Stratified analyses showed the increased HS risk was observed in both genders but only significant in those aged 18-64 years. Kaplan-Meier analysis indicated PSO patients had a higher cumulative probability of developing HS over time (HR 1.77, 95% CI 1.49-1.89).
conclusionsPSO was associated with increased HS risk, highlighting the importance of considering HS as a potential comorbidity in PSO patients and may have implications for early detection, prevention, and management strategies for both conditions. Shared inflammatory pathways, genetic components, and skin dysbiosis may contribute. Further research should elucidate underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.